Nondigestible oligosaccharide

also known as NDO

Developed for: osteoporosis
Investigated by: Baylor College of Medicine · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

today NCT00022867 · Ph 1/2

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1/2	NCT00022867	May 2001 → Jan 2005	osteoporosis	Baylor College of Medicine	Completed	No outcome recorded

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Nondigestible oligosaccharide	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00022867 ↗
Known as	NDO	“Nondigestible oligosaccharide (NDO)” NCT00022867 ↗
Modality	Other / unclassified	“8 g/d of a mixed short and long degree of polymerization inulin-type fructan product” PMID 16087995 ↗ Aug 2005